Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care

Thompson, Ella R., Rowley, Simone M., Li, Na, McInerny, Simone, Devereux, Lisa, Wong-Brown, Michelle W., Trainer, Alison H., Mitchell, Gillian, Scott, Rodney J., James, Paul A., Campbell, Ian G. · 2016 · Journal of Clinical Oncology

Abstract

Purpose: Gene panel sequencing is revolutionizing germline risk assessment for hereditary breast cancer. Despite scant evidence supporting the role of many of these genes in breast cancer predisposition, results are often reported to families as the definitive explanation for their family history. We assessed the frequency of mutations in 18 genes included in hereditary breast cancer panels among index cases from families with breast cancer and matched population controls. Patients and Methods: Cases (n = 2,000) were predominantly breast cancer-affected women referred to specialized Familial Cancer Centers on the basis of a strong family history of breast cancer and BRCA1 and BRCA2 wild type. Controls (n = 1,997) were cancer-free women from the LifePool study. Sequencing data were filtered for known pathogenic or novel loss-of-function mutations. Results: Excluding 19 mutations identified in BRCA1 and BRCA2 among the cases and controls, a total of 78 cases (3.9%) and 33 controls (1.6%) were found to carry potentially actionable mutations. A significant excess of mutations was only observed for PALB2 (26 cases, four controls) and TP53 (five cases, zero controls), whereas no mutations were identified in STK11. Among the remaining genes, loss-of-function mutations were rare, with similar frequency between cases and controls. Conclusion: The frequency of mutations in most breast cancer panel genes among individuals selected for possible hereditary breast cancer is low and, in many cases, similar or even lower than that observed among cancer-free population controls. Although multigene panels can significantly aid in cancer risk management and expedite clinical translation of new genes, they equally have the potential to provide clinical misinformation and harm at the individual level if the data are not interpreted cautiously.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.7454

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 183

Metadata

Authors
Thompson, E. R., Rowley, S. M., Li, N., McInerny, S., Devereux, L., Wong-Brown, M. W., Trainer, A. H., Mitchell, G., Scott, R. J., James, P. A., & Campbell, I. G.
Venue
Journal of Clinical Oncology
Published
2016-05-01
Volume
34
Issue
13
Pages
1455-1459
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2282435866
Cited by
183
References
1
FWCI
25.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. https://app.cochat.ai/papers/10.1200/jco.2015.63.7454
The paper
Thompson, E. R., Rowley, S. M., Li, N., McInerny, S., Devereux, L., Wong-Brown, M. W., Trainer, A. H., Mitchell, G., Scott, R. J., James, P. A., & Campbell, I. G. (2016). Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.63.7454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.